Expertise in
6
conditions

Johanna U. Maenpaa

Pl 100, 
Tampere, FI 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
6
conditions
Pl 100, 
Tampere, FI 

Overview

Johanna Maenpaa practices practicing medicine in Tampere, Finland.

Ms. Maenpaa is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Febrile Neutropenia, Oophorectomy, and Salpingo-Oophorectomy.

She is actively involved in clinical research, co-authoring 88 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

Pl 100, Tampere, 33014, Finland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Two-part, Phase I/Ib, Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase I Part) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase Ib Part) in Patients With Platinum Resistant or Refractory Ovarian Cancer
A Two-part, Phase I/Ib, Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase I Part) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase Ib Part) in Patients With Platinum Resistant or Refractory Ovarian Cancer
Enrollment Status: Recruiting
Publish Date: November 03, 2025
Intervention Type: Biological, Drug
Study Drugs: TILT-123, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer
NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drugs: Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562
Study Phase: Phase 2
View 2 Less Clinical Trial

88 Total Publications

Dyslipidaemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumours.
Dyslipidaemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumours.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 14, 2025

Frequently Asked Questions about Johanna U. Maenpaa

Is Johanna U. Maenpaa a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Johanna U. Maenpaa is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Johanna U. Maenpaa participate in research or clinical trials?

Yes. Johanna U. Maenpaa has published 88 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Johanna U. Maenpaa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Maenpaa's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile